NEW YORK (GenomeWeb News) — Clinical Data today said it has acquired privately held Epidauros Biotechnologie for €8.7 million ($11.8 million) in cash to help flesh out its pharmacogenomics abilities.
Clinical Data said it bought Epidauros for its portfolio of genetic biomarkers, expertise in genetic biomarker discovery, relationships with “leading” diagnostic companies, and its “fast-growing” pharmacogenomics services business.
Clinical Data CEO Drew Fromkin said the buy “will enhance Clinical Data's ability to bring valuable, proprietary pharmacogenetic tests to market.”
As part of the acquisition, Epidauros CEO Michael Lutz will join Clinical Data’s PGxHealth division as senior vice president of pharmacogenetic partnerships.
Epidauros’ intellectual property portfolio includes biomarkers in genes relating to “prominent” drug transporters such as MDR1(1), OCT1(2), MRP1(3), and cytochrome P450 drug metabolizing genes, such as CYP2B6(4) and CYP2D6(5).
MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition, while CYP2B6, OCT1, and MRP1 are believed to help the body absorb, distribute, and metabolize “many drugs that span a variety of therapeutic classes and indications.”
According to Clinical Data, Epidauros will also provide the company with “additional scientific expertise, biotechnology partnering capabilities, and a deep understanding of European clinical markets.”